Home Cart Sign in  
Chemical Structure| 935693-62-2 Chemical Structure| 935693-62-2

Structure of BIX-01294
CAS No.: 935693-62-2

Chemical Structure| 935693-62-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BIX-01294 is a reversible and highly selective G9a and GLP histone methyltransferase inhibitor with IC50 values of 1.7 μM and 0.9 μM, respectively. BIX-01294 competes for binding with amino acids N-terminal of the substrate lysine residue, inducing necroptosis and autophagy, and has antitumor activity in recurrent tumor cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BIX-01294

CAS No. :935693-62-2
Formula : C28H38N6O2
M.W : 490.64
SMILES Code : CN1CCN(C2=NC(NC3CCN(CC4=CC=CC=C4)CC3)=C5C=C(OC)C(OC)=CC5=N2)CCC1
MDL No. :MFCD14560563
InChI Key :OSXFATOLZGZLSK-UHFFFAOYSA-N
Pubchem ID :25150857

Safety of BIX-01294

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of BIX-01294

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bladder cancer cell line J82 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
Bone cancer cell line U2OS 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
Brain cancer cell line U251 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
Breast cancer cell lines MCF10A and MCF7 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
Cervical cancer cell line HeLa 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
Colon cancer cell lines HCT116 and RKO 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
Liver cancer cell line Hep2G 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
Lung cancer cell line H1299 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
Sympathetic nervous system cancer cell lines BE(2)-C, SMS-KCNR, and SHEP1 2–5 μM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined PMC3878056
DPSCs 1 μM 2 weeks BIX-01294 significantly promotes the chondrogenic differentiation of DPSCs, as indicated by the augmented expression levels of cartilage-signature markers and markedly increased proteoglycans. PMC10460901
HCT116 cells 5 µM 24 hours To examine the effect of BIX-01294 on FOXO1 methylation, results showed decreased FOXO1 methylation levels PMC6393239
DLD-1 cells 5 µM 24 hours To examine the effect of BIX-01294 on FOXO1 methylation, results showed decreased FOXO1 methylation levels PMC6393239
SW480 cells 5 µM 24 hours To examine the effect of BIX-01294 on FOXO1 methylation, results showed decreased FOXO1 methylation levels PMC6393239
HEY cells 5 μM 24 hours BIX-01294 significantly up-regulated the transcriptional expression of SLC31A1 and reduced the IC50 value of CDDP, increasing CDDP sensitivity. PMC8441092
SKOV3 cells 5 μM 24 hours BIX-01294 significantly up-regulated the transcriptional expression of SLC31A1 and reduced the IC50 value of CDDP, increasing CDDP sensitivity. PMC8441092
JEG-3 placental choriocarcinoma cells 3.3 µM 3 days BIX-01294 showed an IC50 value of 3.3 μM in JEG-3 cells, demonstrating selectivity for the parasite. PMC3478629
Human foreskin fibroblasts (HFF) 6.1 µM 3 days BIX-01294 showed an IC50 value of 6.1 μM in HFF cells, demonstrating selectivity for the parasite. PMC3478629
Mouse embryonic fibroblasts (MEF) 11 µM 3 days BIX-01294 showed an IC50 value of 11 μM in MEF cells, demonstrating selectivity for the parasite. PMC3478629
Plasmodium falciparum 3D7 100 nM 3 hours BIX-01294 and TM2-115 inhibited P. falciparum 3D7 parasites in culture with IC50 values of ~100 nM, and significantly reduced parasite viability within 3 hours. PMC3478629
KG1 cells 10 μM 48 hours BIX-01294 activated the PERK/NRF2 pathway and upregulated HO-1 expression, suppressing p38 phosphorylation and intracellular ROS generation, thereby inhibiting apoptosis in KG1 cells. PMC7158163
U937 cells 10 μM 48 hours BIX-01294 markedly induced p38 phosphorylation and apoptosis in U937 cells. PMC7158163
EGFR-mutant NSCLC cells (PC9 and H1975) 10 µM 48 hours BIX significantly induced apoptosis and activated effector caspase-3 and PARP. PMC8741967
EGFR-WT NSCLC cells (H460 and A549) 10 µM 48 hours BIX had no significant apoptotic effect on EGFR-WT cells. PMC8741967
K-ras NIH 3T3 transformed cells 2.5 µM 72 hours BIX-01294 treatment reversed Ras-mediated epigenetic silencing of the Fas gene, similar to the effect of 5-aza treatment. PMC2676930

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
severe combined immunodeficiency mice EGFR-mutant NSCLC xenograft model intraperitoneally 5 mg/kg or 10 mg/kg 2 days a week for 4 weeks BIX significantly inhibited the growth of EGFR-mutant tumors and reduced EGFR expression. PMC8741967
Nude mice intra-peritoneal tumor model intra-peritoneal injection 5 mg/kg twice a week for six weeks BIX-01294 significantly reduced tumor growth and prolonged the survival time of tumor-bearing mice, increasing CDDP sensitivity. PMC8441092
Mice Plasmodium berghei ANKA infection model Intraperitoneal injection 40 mg/kg Single dose A single intraperitoneal dose of 40 mg/kg BIX-01294 reduced parasitemia by 2-fold in mice, and the mice survived for more than 3 weeks post-infection. PMC3478629

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.19mL

2.04mL

1.02mL

20.38mL

4.08mL

2.04mL

References

 

Historical Records

Categories